Products Affected - Description
Chloroquine tablets, Ranbaxy
250 mg, 50 count (NDC 63304-0460-50)
500 mg, 25 count (NDC 63304-0461-26)
Chloroquine tablets, West-Ward
500 mg, 25 count (NDC 00143-2125-22)
Reason for the Shortage
- Global Pharmaceuticals discontinued chloroquine tablets in 2014.
- Rising has chloroquine tablets available.
- Ranbaxy has chloroquine tablets on shortage due to third party supply issues.
- West-Ward has chloroquine tablets on shortage due to manufacturing delays.
Chloroquine tablet, Rising Pharmaceuticals
250 mg, 50 count (NDC 64980-0177-50)
500 mg, 25 count (NDC 64980-0178-02)
Estimated Resupply Dates
- Ranbaxy has chloroquine tablets on long-term back order and the company cannot estimate a release date.
- West-Ward has chloroquine tablets on back order and the company cannot estimate a release date.
June 17, 2016; March 10, November 30, October 15, September 17, August 24, July 22, June 29, May 27, April 21, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins